Prelude Therapeutics Incorporated announced that Jane Huang, M.D., has been appointed to the newly created position of President and Chief Medical Officer, effective on April 4, 2022. Dr. Huang is currently Chief Medical Officer, Hematology, at BeiGene Ltd. Prior to joining BeiGene in 2016, Dr. Huang served as Vice President, Clinical Development at Acerta Pharma.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.09 USD | -0.73% | +5.96% | -4.22% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.22% | 226M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- PRLD Stock
- News Prelude Therapeutics Incorporated
- Prelude Therapeutics Incorporated Appoints Jane Huang as President and Chief Medical Officer, Effective April 4, 2022